By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Catabasis Pharmaceuticals, Inc. 

161 First Street
Suite 1A
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-349-1971 Fax: 617-273-2637


SEARCH JOBS


Industry
Pharmaceutical






Company News
Catabasis (CATB) Reports Fourth Quarter And Full Year 2016 Financial Results And Recent Corporate Highlights 3/17/2017 6:30:08 AM
Catabasis (CATB) To Report Fourth Quarter And Full Year 2016 Financial Results And Recent Corporate Developments On Thursday, March 16 3/2/2017 6:17:38 AM
Catabasis (CATB) Announces Promotion Of Ted Hibben To Chief Business Officer 2/17/2017 6:54:00 AM
Catabasis (CATB) Plunges on DMD Drug Trial Failure 2/1/2017 5:22:28 AM
Catabasis (CATB) Release: Company's Phase I Data On Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy Being Developed For Duchenne Muscular Dystrophy, Published In The Journal Of Clinical Pharmacology 1/19/2017 7:41:44 AM
Catabasis (CATB) Research On CAT-5571, A Novel Activator Of Autophagy And Potential Oral Treatment For Cystic Fibrosis, Published In Journal Of Medicinal Chemistry 1/5/2017 8:50:51 AM
Catabasis (CATB) Release: Positive Preclinical Research On The Edasalonexent (CAT-1004) Program, A Potential Disease-Modifying Therapy For Duchenne Muscular Dystrophy, Published In JCI Insight 1/4/2017 11:13:42 AM
Catabasis (CATB) Provides Edasalonexent And Rare Disease Pipeline Updates At Investor Day 11/17/2016 8:05:09 AM
Catabasis (CATB) Reports Third Quarter 2016 Financial Results And Recent Corporate Highlights 11/11/2016 12:54:40 PM
Catabasis (CATB) Presents Positive Data For CAT-5571, A Novel Activator Of Autophagy, As A Potential Oral Treatment For Cystic Fibrosis At The 30th Annual North American Cystic Fibrosis Conference 10/27/2016 10:44:15 AM
12345678910...
//-->